There O
was O
significant O
improvement O
in O
creatinine B-Physiological-Clinical

The O
poor O
metabolizer O
demonstrated O
in O
both O
oral O
formulations O
high B-Physiological-Clinical
plasma I-Physiological-Clinical
concentrations I-Physiological-Clinical
, O
increased O
AUCs O
and O
prolonged O
terminal O
half-lives O
as O
well O
as O
increased O
renal B-Physiological-Clinical
excretion I-Physiological-Clinical
of I-Physiological-Clinical
prajmalium I-Physiological-Clinical

Experiment O
3 O
showed O
that O
increases O
in O
target-distractor B-Life-Impact
similarity O
slowed O
the O
visual B-Life-Impact
search I-Life-Impact
performance B-Life-Impact
of O
the O
control O
group O
significantly O
more O
than O
that O
of O
the O
autism O
group O
, O
suggesting O
that O
the O
adults O
with O
autism O
have O
a O
superior B-Physiological-Clinical
visual I-Physiological-Clinical
discrimination I-Physiological-Clinical

Between-group O
differences O
from O
baseline O
in O
mean O
MSQ B-Physiological-Clinical

Two O
CMZ O
patients O
and O
one O
morphine O
patient O
showed O
complete O
pain B-Physiological-Clinical

CONCLUSIONS O
This O
study O
shows O
a O
beneficial O
effect O
on O
oral B-Physiological-Clinical

Random-effects O
regression O
models O
over O
the O
first O
4 O
years O
after O
randomization O
revealed O
that O
, O
although O
the O
intervention O
did O
not O
affect O
the O
frequency O
of O
patient O
behavioral O
problems O
, O
it O
did O
significantly O
reduce O
caregivers B-Life-Impact
' O
reaction B-Life-Impact

The O
corresponding O
1-year O
mortality B-Mortality

No O
change O
occurred O
in O
HDL B-Physiological-Clinical
cholesterol B-Physiological-Clinical
, O
apo B-Physiological-Clinical
B100/apo B-Physiological-Clinical
A1 B-Physiological-Clinical
ratio O
, O
plasminogen B-Physiological-Clinical
activator B-Physiological-Clinical
inhibitor I-Physiological-Clinical

EMG-EMG O
coherence O
analyses O
revealed O
that O
elbow B-Physiological-Clinical
muscle I-Physiological-Clinical
activation I-Physiological-Clinical
significantly O
reduced O
intermuscular B-Physiological-Clinical
coherence O
between O
distal B-Physiological-Clinical
muscle I-Physiological-Clinical

Secondary O
outcomes O
included O
changes O
in O
markers B-Physiological-Clinical
of I-Physiological-Clinical
bone I-Physiological-Clinical
resorption I-Physiological-Clinical
( I-Physiological-Clinical
urine I-Physiological-Clinical
N-telopeptide I-Physiological-Clinical
cross-linked I-Physiological-Clinical
collagen I-Physiological-Clinical
type O
I O
) O
and O
formation B-Physiological-Clinical
( O
osteocalcin B-Physiological-Clinical
, O
N-terminal B-Physiological-Clinical
propeptide I-Physiological-Clinical

Significantly O
more O
ALA-PDT O
warts O
were O
graded O
at O
a O
higher O
pain B-Physiological-Clinical

4 O
There O
was O
a O
significantly O
greater O
fall B-Physiological-Clinical
in I-Physiological-Clinical
pulse I-Physiological-Clinical

RESULTS O
At O
Months O
12 O
and O
24 O
, O
ranibizumab O
was O
superior O
to O
PDT O
( O
P O
< O
0.0001 O
) O
for O
mean O
changes O
from O
baseline O
in O
total O
area O
of O
lesion B-Physiological-Clinical
, O
CNV B-Physiological-Clinical
area O
, O
and O
total O
area O
CNV B-Physiological-Clinical

Complete B-Physiological-Clinical
relief I-Physiological-Clinical

In O
our O
patients O
pericarditis O
encompassed O
a O
wide O
spectrum O
ranging O
from O
a O
mild B-Physiological-Clinical
illness I-Physiological-Clinical
of I-Physiological-Clinical
several I-Physiological-Clinical
days O
duration B-Physiological-Clinical
to O
a O
painful O
and O
debilitating B-Physiological-Clinical

The O
incidence O
of O
ARDS B-Physiological-Clinical
due I-Physiological-Clinical
to I-Physiological-Clinical
pulmonary I-Physiological-Clinical
infection I-Physiological-Clinical
was I-Physiological-Clinical
higher O
in O
the O
G-CSF B-Physiological-Clinical

The O
experimental O
group O
had O
significant O
gains O
in O
knowledge B-Life-Impact
related I-Life-Impact
to I-Life-Impact
anatomy I-Life-Impact
and I-Life-Impact
physiology I-Life-Impact
, O
diet B-Life-Impact
, O
and O
lifestyle B-Life-Impact
risk O
factors O
associated O
with O
the O
development O
of O
heart B-Physiological-Clinical
disease I-Physiological-Clinical

The O
objectives O
of O
this O
trial O
are O
to O
determine O
whether O
tamoxifen O
is O
effective O
in O
1 O
) O
reducing O
the O
incidence O
of O
invasive B-Physiological-Clinical
breast I-Physiological-Clinical
cancer B-Physiological-Clinical
, O
2 O
) O
reducing O
breast B-Mortality
cancer I-Mortality
mortality I-Mortality
, O
3 O
) O
reducing O
deaths B-Mortality
from O
cardiovascular B-Physiological-Clinical

Patients O
with O
complete B-Physiological-Clinical
response O
( O
CR B-Physiological-Clinical

CONCLUSION O
TTS-scopolamine O
offers O
effective O
prophylaxis B-Resource-use
against O
PONV B-Physiological-Clinical
( I-Physiological-Clinical
auriculoemetic I-Physiological-Clinical

There O
were O
also O
no O
significant O
differences O
between O
treatment O
groups O
in O
cardiovascular B-Physiological-Clinical
effects I-Physiological-Clinical
, O
laboratory B-Physiological-Clinical
values O
, O
or O
adverse B-Adverse-effects

Levels O
of O
urinary B-Physiological-Clinical
estrogen I-Physiological-Clinical

Data O
from O
this O
study O
indicate O
that O
consumption O
of O
medium-and O
long-chain O
triglycerides O
can O
reduce O
body B-Physiological-Clinical
weight I-Physiological-Clinical
and O
body B-Physiological-Clinical

These O
tests O
showed O
a O
total O
failure O
of O
the O
benzimidazole B-Resource-use
, O
imidothiazole B-Resource-use
, O
macrocyclic B-Physiological-Clinical
lactone I-Physiological-Clinical
and O
salicylanilide B-Resource-use

The O
resulting O
magnitude O
estimation O
ratings O
of O
symptom B-Life-Impact

The O
primary O
endpoint O
was O
death B-Mortality
, O
myocardial B-Physiological-Clinical

Serum B-Physiological-Clinical
folate I-Physiological-Clinical
and O
vitamin B-Physiological-Clinical
B12 I-Physiological-Clinical

Secondary O
outcomes O
will O
be O
measured O
at O
30 O
minutes O
after O
treatment O
using O
the O
NRS O
of O
leg B-Physiological-Clinical
pain I-Physiological-Clinical
, O
ODI B-Physiological-Clinical
, O
patient B-Physiological-Clinical
global I-Physiological-Clinical
impression I-Physiological-Clinical
of I-Physiological-Clinical
change I-Physiological-Clinical
, O
range O
of O
motion B-Physiological-Clinical
( O
ROM B-Physiological-Clinical
) O
of O
the O
lumbar B-Physiological-Clinical
spine I-Physiological-Clinical
, O
and O
degrees O
of O
straight B-Physiological-Clinical
leg B-Physiological-Clinical

Thus O
, O
the O
severity O
of O
a O
specific B-Life-Impact
behavioral I-Life-Impact
dimension I-Life-Impact
in O
autism O
( O
repetitive B-Life-Impact
behaviors I-Life-Impact
) O
parallels B-Life-Impact

Mean O
HbA B-Physiological-Clinical
( I-Physiological-Clinical
1c I-Physiological-Clinical

CONCLUSION O
Age O
and O
gender O
, O
as O
well O
as O
the O
severity O
of O
cardiac O
dysfunction O
, O
appear O
to O
have O
an O
important O
effect O
on O
the O
severity O
of O
heart B-Physiological-Clinical
failure I-Physiological-Clinical

Neonatal O
naloxone B-Resource-use

Pretreatment O
with O
valproate O
as O
compared O
to O
placebo O
reduced O
the O
velocity B-Physiological-Clinical
in O
both O
middle B-Physiological-Clinical
cerebral I-Physiological-Clinical

In O
experimental O
study O
, O
monoaminic B-Physiological-Clinical
transmitters I-Physiological-Clinical
activated O
in O
hypothalamus O
; O
weight O
of O
pituitary B-Physiological-Clinical
, O
adrenal B-Physiological-Clinical
and O
thymus B-Physiological-Clinical
decreased O
; O
number O
of O
CRH B-Physiological-Clinical
positive I-Physiological-Clinical
neurons I-Physiological-Clinical
in I-Physiological-Clinical
hypothalamic I-Physiological-Clinical
paraventricular I-Physiological-Clinical
nucleus B-Physiological-Clinical
, O
CRH B-Physiological-Clinical
positive I-Physiological-Clinical
neurofibrilin B-Physiological-Clinical
median O
eminence B-Physiological-Clinical
and O
anterior B-Physiological-Clinical
pituitary I-Physiological-Clinical
ACTH B-Physiological-Clinical
positive I-Physiological-Clinical
secretory I-Physiological-Clinical
cells I-Physiological-Clinical
decreased O
; O
adrenal B-Physiological-Clinical
fasciculate B-Physiological-Clinical

In O
the O
post-therapy O
period O
, O
there O
were O
no O
group O
differences O
in O
special B-Life-Impact
education I-Life-Impact

Markers O
of O
bone B-Physiological-Clinical
metabolism I-Physiological-Clinical
- O
- O
serum O
total O
alkaline B-Physiological-Clinical
phosphatase B-Physiological-Clinical
, O
bone-specific B-Physiological-Clinical
alkaline B-Physiological-Clinical
phosphatase I-Physiological-Clinical
, O
tartrate-resistant B-Physiological-Clinical
acid B-Physiological-Clinical
phosphatase I-Physiological-Clinical
, O
osteocalcin B-Physiological-Clinical
, O
intact B-Physiological-Clinical

There O
was O
no O
significant O
difference O
between O
treatment O
groups O
in O
the O
percentage O
of O
patients O
who O
experienced O
a O
clinical B-Adverse-effects
adverse I-Adverse-effects

Independent O
predictors O
of O
PFS O
included O
race O
, O
performance B-Physiological-Clinical
status B-Physiological-Clinical
, O
disease B-Physiological-Clinical

No O
allergic B-Physiological-Clinical
reactions I-Physiological-Clinical
, O
increased O
respiratory B-Physiological-Clinical

Patients O
able O
to O
sit O
in O
a O
chair O
( O
n O
= O
65 O
) O
, O
who O
mostly O
had O
less O
severe O
strokes O
, O
had O
a O
significantly O
higher O
mean O
SaO B-Physiological-Clinical
( O
2 O
) O
and O
heart B-Physiological-Clinical

The O
group O
treated O
by O
a O
medical O
nurse O
without O
training O
in O
psychotherapy O
experienced O
sustained O
relief O
of O
dyspnoea B-Physiological-Clinical
but O
tended O
to O
undergo O
less O
psychodynamic B-Life-Impact
change I-Life-Impact
; O
psychiatric B-Physiological-Clinical

Indomethacin O
abolished O
the O
prostacyclin B-Resource-use

Key O
secondary O
endpoints O
included O
target B-Physiological-Clinical
vessel I-Physiological-Clinical
failure I-Physiological-Clinical
( O
TVF B-Physiological-Clinical
; O
including O
cardiac B-Physiological-Clinical
death B-Mortality
, O
myocardial B-Physiological-Clinical
infarction I-Physiological-Clinical
, O
and O
target B-Physiological-Clinical
vessel I-Physiological-Clinical
revascularization I-Physiological-Clinical
) O
and O
Academic B-Physiological-Clinical
Research I-Physiological-Clinical
Consortium-defined I-Physiological-Clinical
definite/probable I-Physiological-Clinical

Heart B-Physiological-Clinical
rate I-Physiological-Clinical
, O
stroke B-Physiological-Clinical

However O
, O
during O
the O
whole O
12-month O
training O
period O
, O
both O
dynamic B-Physiological-Clinical
and O
isometric B-Physiological-Clinical
back B-Physiological-Clinical
extension I-Physiological-Clinical

At O
follow-up O
, O
39 O
% O
of O
conservative O
management O
patients O
requested O
surgery O
, O
and O
interference O
of O
symptoms B-Physiological-Clinical

CONCLUSIONS O
The O
laparoscopic O
surgery O
in O
combination O
of O
QYJDR O
could O
effectively O
improve O
clinical O
symptoms O
of O
EMs O
patients O
of O
blood B-Physiological-Clinical
stasis I-Physiological-Clinical
and O
toxin B-Physiological-Clinical
accumulation I-Physiological-Clinical
syndrome I-Physiological-Clinical
, O
promote O
negative O
conversion B-Physiological-Clinical
of I-Physiological-Clinical
EMAb I-Physiological-Clinical
, O
lower O
serum B-Physiological-Clinical
CA125 I-Physiological-Clinical

Using O
a O
logistic O
regression O
model O
, O
baseline O
quantitative B-Physiological-Clinical
mycobacterial I-Physiological-Clinical

Levels O
of O
complement B-Physiological-Clinical
factor O
C3a B-Physiological-Clinical
( O
851 O
( O
791-959 O
) O
ng/ml O
[ O
median O
with O
quartiles O
] O
in O
group O
C O
, O
497 O
( O
476-573 O
) O
ng/ml O
in O
group O
HC O
, O
p O
< O
0.001 O
) O
, O
Terminal B-Physiological-Clinical

Unlike O
intracoronary O
brachytherapy O
, O
there O
was O
no O
evidence O
of O
negative O
edge O
effects O
, O
unhealed B-Physiological-Clinical
dissections I-Physiological-Clinical
, O
or I-Physiological-Clinical
late I-Physiological-Clinical
stent-vessel I-Physiological-Clinical
wall I-Physiological-Clinical

However O
, O
the O
P/S B-Physiological-Clinical
ratio I-Physiological-Clinical
was O
not O
significantly O
affected O
, O
partly O
because O
the O
relative O
content O
of O
saturated B-Physiological-Clinical
fatty I-Physiological-Clinical

Change O
in O
CPSD B-Physiological-Clinical

Treatment O
with O
simvastatin O
or O
gemfibrozil O
in O
hypertensive O
patients O
in O
hydrochlorothiazide O
monotherapy O
can O
reduce O
total O
cholesterol B-Physiological-Clinical
and O
LDL-cholesterol B-Physiological-Clinical

During O
the O
fifth O
and O
sixth O
cycles O
of O
combination O
therapy O
94 O
% O
of O
cycles O
were O
free B-Physiological-Clinical
of I-Physiological-Clinical
flushing I-Physiological-Clinical
( O
vs O
. O
31 O
% O
for O
control O
, O
P O
< O
0.01 O
) O
, O
64 O
% O
of O
cycles O
were O
free B-Physiological-Clinical
of I-Physiological-Clinical
spotting I-Physiological-Clinical
not O
requiring B-Life-Impact
protection I-Life-Impact
( O
control O
75 O
% O
) O
, O
96 O
% O
of O
cycles O
were O
free B-Physiological-Clinical
of I-Physiological-Clinical
vaginal I-Physiological-Clinical
bleeding B-Physiological-Clinical
( O
control O
100 O
% O
) O
, O
endometrial O
biopsy O
showed O
inactive B-Physiological-Clinical
endometrium I-Physiological-Clinical
in O
nine O
of O
the O
10 O
subjects O
re-biopsied O
, O
fasting B-Physiological-Clinical
blood I-Physiological-Clinical

Patients O
' O
postoperative O
pain B-Physiological-Clinical
, O
anxiety B-Life-Impact
, O
blood B-Physiological-Clinical

RESULTS O
No O
significant O
differences O
were O
observed O
between O
the O
two O
groups O
with O
regard O
to O
the O
maximum O
diameters B-Physiological-Clinical
and O
calculated O
area O
of O
the O
resected O
specimens B-Physiological-Clinical
( O
ligation O
group O
: O
16.4 O
[ O
4.0 O
] O
x O
11 O
[ O
3.1 O
] O
mm/185 O
[ O
84 O
] O
mm O
( O
2 O
) O
vs O
. O
cap O
group O
: O
15.5 O
[ O
4.1 O
] O
x O
10.7 O
[ O
2.7 O
] O
mm/168 O
[ O
83 O
] O
mm O
( O
2 O
) O
) O
, O
or O
the O
maximum O
diameters B-Physiological-Clinical

The O
PI B-Physiological-Clinical
, O
mmax O
and O
maximal O
transdiaphragmatic B-Physiological-Clinical

Mean O
arterial B-Physiological-Clinical
pressure B-Physiological-Clinical
was O
inversely O
related O
to O
total O
and O
cardiovascular B-Physiological-Clinical

The O
quality O
of O
pain B-Physiological-Clinical
control O
, O
the O
amount O
and O
character O
of O
the O
drain O
fluid B-Physiological-Clinical
, O
incidence O
of O
nausea B-Physiological-Clinical
and O
vomiting B-Physiological-Clinical
, O
length B-Resource-use
of I-Resource-use
stay I-Resource-use

All O
patients O
showed O
a O
mild-to-moderate O
decrease O
in O
baseline O
forced B-Physiological-Clinical

Liver B-Physiological-Clinical
and O
renal B-Physiological-Clinical

Serum B-Physiological-Clinical
free I-Physiological-Clinical

Documented O
histologic B-Physiological-Clinical
conversion B-Life-Impact
was O
often O
associated O
with O
a O
more O
aggressive B-Life-Impact
clinical I-Life-Impact

In O
conclusion O
, O
endurance O
training O
favorably O
affects O
blood B-Physiological-Clinical
lipoprotein B-Physiological-Clinical

The O
factorial O
analysis O
showed O
that O
both O
1000 O
mg O
acetaminophen O
and O
60 O
mg O
codeine O
made O
a O
statistically O
significant O
( O
P O
less O
than O
0.05 O
) O
contribution O
to O
the O
analgesic B-Resource-use
effectiveness O
of O
the O
combination O
on O
all O
measures O
of O
efficacy O
( O
sum O
of O
pain B-Physiological-Clinical
intensity O
differences O
, O
largest O
pain B-Physiological-Clinical
intensity O
difference O
, O
total O
pain B-Physiological-Clinical
relief I-Physiological-Clinical
, O
largest O
pain B-Physiological-Clinical

The O
primary O
efficacy O
variable O
was O
the O
change O
from O
baseline O
in O
the O
total O
nasal B-Physiological-Clinical
symptom I-Physiological-Clinical
score O
( O
TNSS B-Physiological-Clinical
) O
, O
consisting O
of O
nasal B-Physiological-Clinical
congestion B-Physiological-Clinical
, O
runny B-Physiological-Clinical
nose B-Physiological-Clinical
, O
itchy B-Physiological-Clinical

There O
was O
a O
significant O
reduction O
in O
the O
mean O
of O
metabolic B-Physiological-Clinical
syndrome I-Physiological-Clinical

No O
statistically O
significant O
difference O
was O
found O
in O
the O
use O
of O
instrumental B-Physiological-Clinical
vaginal I-Physiological-Clinical

The O
ACTH-stimulated B-Physiological-Clinical
mean O
cortisol B-Physiological-Clinical

Longitudinal O
regression O
analyses O
that O
followed O
participants O
throughout O
the O
treatment O
period O
showed O
significantly O
greater O
downward O
slopes O
per O
week O
on O
the O
10 O
point O
arm O
pain B-Physiological-Clinical

Findings O
indicated O
that O
high-BP O
individuals O
showed O
heightened B-Life-Impact

Results O
showed O
that O
diphenhydramine O
produced O
a O
significant O
inhibition B-Physiological-Clinical
of O
the O
histamine-induced B-Physiological-Clinical
wheal I-Physiological-Clinical
size I-Physiological-Clinical
at O
1.5 O
h O
which O
lasted O
up O
to O
4 O
h O
after O
drug O
administration O
, O
reaching O
maximum O
inhibition O
at O
2.5 O
h O
. O
After O
cinnarizine O
treatment O
no O
significant O
decrease O
of O
the O
histamine-induced B-Physiological-Clinical

CONCLUSIONS O
In O
patients O
with O
iron O
deficiency O
anemia O
due O
to O
heavy O
uterine O
bleeding O
, O
rapid O
IV O
administration O
of O
large O
doses O
of O
a O
new O
iron O
agent O
, O
ferric O
carboxymaltose O
, O
is O
more O
effective O
than O
oral O
iron O
therapy O
in O
correcting B-Physiological-Clinical
anemia I-Physiological-Clinical
, O
replenishing B-Physiological-Clinical

Rye O
bran O
intervention O
had O
no O
influence O
on O
lag O
time O
or O
propagation B-Physiological-Clinical

Cephalometric B-Physiological-Clinical
measures I-Physiological-Clinical
showed O
a O
significant O
decrease O
in O
anterior B-Physiological-Clinical
lower O
facial B-Physiological-Clinical

CONCLUSION O
The O
treatment O
with O
probucol O
can O
improve O
oxidative B-Physiological-Clinical
stress O
in O
hypertension B-Physiological-Clinical
patients O
, O
resulting O
in O
reduced O
serum B-Physiological-Clinical
MDA I-Physiological-Clinical

However O
, O
no O
significant O
differences O
in O
the O
number O
of O
episodes O
of O
vomiting B-Physiological-Clinical
, O
the O
severity O
of O
nausea B-Physiological-Clinical
or O
clinical B-Physiological-Clinical

While O
the O
PSA B-Physiological-Clinical

Moreover O
, O
percentage O
change O
of O
monocyte B-Physiological-Clinical
chemoattractant I-Physiological-Clinical

No O
women O
given O
metformin O
spontaneously B-Physiological-Clinical

The O
slope O
of O
the O
regression O
line O
for O
the O
delta O
melanin B-Resource-use
index O
against O
delta O
erythema B-Physiological-Clinical

Matched O
HR O
for O
death B-Mortality

RESULTS O
Raw O
scores O
, O
age-equivalents O
, O
and O
special O
norm O
percentile O
scores O
all O
showed O
significant O
increases O
in O
adaptive B-Life-Impact
behavior I-Life-Impact
in I-Life-Impact
the I-Life-Impact
areas I-Life-Impact
of I-Life-Impact
communication I-Life-Impact
, O
daily O
living B-Life-Impact
skills I-Life-Impact

In O
line O
with O
earlier O
investigations O
, O
our O
results B-Physiological-Clinical
suggest I-Physiological-Clinical
a O
moderate O
- O
potentially O
clinically B-Physiological-Clinical

In O
both O
arms O
combined O
, O
declines O
from O
baseline O
to O
3 O
months O
were O
observed O
in O
sexual B-Life-Impact
risk O
behaviors B-Life-Impact
, O
social B-Life-Impact

Six O
couples O
did O
not O
attempt B-Life-Impact
intercourse I-Life-Impact
despite O
a O
professed O
interest O
in O
sexual B-Life-Impact

Best-corrected B-Physiological-Clinical
visual I-Physiological-Clinical
acuity B-Physiological-Clinical
( O
Early O
Treatment O
Diabetic B-Physiological-Clinical
Retinopathy I-Physiological-Clinical
Study B-Life-Impact
chart O
) O
, O
intraocular B-Physiological-Clinical
pressure I-Physiological-Clinical
measurement O
, O
biomicroscopy B-Physiological-Clinical
, O
funduscopy B-Resource-use
, O
digital B-Resource-use
fluorescein I-Resource-use

RESULTS O
Four O
( O
1.3 O
% O
) O
patients O
were O
excluded O
because O
of O
unbearable B-Physiological-Clinical
pain I-Physiological-Clinical
during O
the O
procedure O
, O
leaving O
Group O
1 O
with O
98 O
patients O
, O
Group O
2 O
with O
99 O
, O
and O
Group O
3 O
with O
99 O
; O
the O
3 O
groups O
were O
comparable O
for O
patients O
' O
age O
, O
serum B-Physiological-Clinical
PSA I-Physiological-Clinical
, O
prostate B-Physiological-Clinical
volume I-Physiological-Clinical
, O
and O
cancer B-Physiological-Clinical
detection I-Physiological-Clinical

The O
odds O
ratio O
associated O
with O
the O
fibre O
treatment O
was O
significantly O
higher O
in O
participants O
with O
baseline O
dietary O
calcium O
intake O
above O
the O
median O
than O
in O
those O
with O
intake O
below O
the O
median O
( O
interaction O
test O
, O
p=0.028 O
) O
INTERPRETATION O
Supplementation O
with O
fibre O
as O
ispaghula O
husk O
may O
have O
adverse B-Adverse-effects
effects I-Adverse-effects

In O
contrast O
, O
serum B-Physiological-Clinical
insulin I-Physiological-Clinical
levels O
, O
C-peptide B-Physiological-Clinical

Multivariate O
logistic O
analysis O
showed O
that O
insulin O
treatment O
was O
the O
only O
independent O
predictor O
of O
MACE B-Physiological-Clinical
[ O
odds O
ratio O
( O
OR O
) O
8.60 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
3.25-22.76 O
, O
P O
< O
0.001 O
] O
and O
target B-Physiological-Clinical
vessel B-Physiological-Clinical
revascularization I-Physiological-Clinical
( O
TVR B-Physiological-Clinical

RESULTS O
No O
patients O
showed O
signs O
of O
respiratory B-Physiological-Clinical

Olanzapine O
may O
be O
a O
promising O
treatment O
for O
improving O
global B-Physiological-Clinical

However O
, O
placebo O
showed O
little O
effect O
on O
these O
lipid B-Physiological-Clinical
levels O
, O
urinary B-Physiological-Clinical
protein B-Physiological-Clinical
excretion I-Physiological-Clinical
and O
urinary B-Physiological-Clinical
podocyte I-Physiological-Clinical

Frequency O
of O
nasal B-Physiological-Clinical

The O
prevalences O
of O
clinical B-Adverse-effects
adverse I-Adverse-effects

Moreover O
, O
the O
incidence O
of O
overall B-Physiological-Clinical
recurrent I-Physiological-Clinical
thromboembolic I-Physiological-Clinical

Although O
the O
electrophysiologic O
changes O
induced O
by O
these O
antiarrhythmic O
agents O
contributed O
to O
facilitating O
pacing-induced O
termination O
, O
neither O
tachycardia B-Physiological-Clinical
cycle O
length B-Physiological-Clinical
nor O
action B-Physiological-Clinical
potential I-Physiological-Clinical

Hypothyroidism O
resulted O
in O
hyperfibrinolysis B-Physiological-Clinical
and O
a O
reduced O
TAFIa-dependent B-Physiological-Clinical
prolongation I-Physiological-Clinical
of I-Physiological-Clinical
clot B-Physiological-Clinical

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
regarding O
the O
development O
of O
ventricular B-Physiological-Clinical
arrhythmia I-Physiological-Clinical
, O
duration O
of O
cardiopulmonary B-Physiological-Clinical
bypass I-Physiological-Clinical
, O
intra-aortic B-Physiological-Clinical
balloon I-Physiological-Clinical
pump I-Physiological-Clinical
and O
inotropic B-Physiological-Clinical
support O
requirement O
, O
duration O
of O
mechanical B-Resource-use
ventilation I-Resource-use
, O
duration O
of O
intensive B-Resource-use
care I-Resource-use

Cardiovascular B-Physiological-Clinical
( I-Physiological-Clinical
heart I-Physiological-Clinical
rate O
and O
arterial B-Physiological-Clinical

On O
the O
primary O
outcome O
measure O
, O
the O
Ohio O
Autism B-Life-Impact

Total O
suture B-Physiological-Clinical

The O
triglyceride B-Physiological-Clinical
and O
high-density B-Physiological-Clinical
lipoprotein I-Physiological-Clinical
cholesterol B-Physiological-Clinical

Patients O
selected O
for O
moderately O
progressive B-Physiological-Clinical
IgA I-Physiological-Clinical

The O
cancer B-Physiological-Clinical
detection I-Physiological-Clinical

RESULTS O
The O
incidence O
of O
reperfusion B-Physiological-Clinical
arrhythmias-frequent I-Physiological-Clinical

CONCLUSION O
Oral O
magnesium O
supplementation O
helped O
improve O
both O
the O
SK O
score O
and O
respiratory B-Physiological-Clinical
muscle I-Physiological-Clinical

The O
change O
in O
hsCRP B-Physiological-Clinical
was O
associated O
with O
apnea-hypopnea B-Physiological-Clinical

No O
bilateral B-Physiological-Clinical
adnexal I-Physiological-Clinical

There O
was O
a O
trend O
of O
a O
reduced O
proportion O
of O
rapid B-Physiological-Clinical
eye I-Physiological-Clinical
movement I-Physiological-Clinical
sleep I-Physiological-Clinical
with O
increased O
exercise B-Life-Impact

In O
adjusted O
analyses O
, O
parents O
who O
reported O
that O
their O
child O
had O
ASD O
did O
not O
have O
significantly O
higher O
out-of-pocket B-Resource-use

Total O
control B-Physiological-Clinical
( O
no O
vomiting B-Physiological-Clinical
, O
no O
retching B-Physiological-Clinical
, O
no O
nausea B-Physiological-Clinical
, O
and O
no O
use B-Life-Impact
of O
antiemetic B-Resource-use

CONCLUSIONS O
The O
use O
of O
skull O
block O
during O
EDAMS O
surgery O
provided O
easy O
hemodynamic B-Physiological-Clinical
control O
, O
calm B-Life-Impact

RESULTS O
The O
administration O
of O
ginseng O
extract O
resulted O
in O
a O
significant O
improvement O
of O
fertility B-Physiological-Clinical
parameters O
and O
testicular B-Physiological-Clinical
antioxidants I-Physiological-Clinical
together O
with O
a O
decrease O
in O
malondialdehyde B-Physiological-Clinical
and O
testicular B-Physiological-Clinical

Initiation B-Life-Impact

In O
conclusion O
, O
we O
investigated O
SNP-diet B-Physiological-Clinical
interactions I-Physiological-Clinical
for I-Physiological-Clinical
blood I-Physiological-Clinical
lipid I-Physiological-Clinical

Conversely O
, O
plasma B-Physiological-Clinical
potassium I-Physiological-Clinical
increased O
and O
blood B-Physiological-Clinical

The O
rescue B-Resource-use
analgesic I-Resource-use

GLP-1 O
did O
not O
change O
perception O
of O
isobaric B-Physiological-Clinical
distension I-Physiological-Clinical
but O
reduced O
the O
perception B-Life-Impact

Mean O
modification B-Physiological-Clinical

Resolution O
( O
i.e O
. O
, O
the O
proportion O
of O
patients O
with O
signs B-Physiological-Clinical

The O
number O
of O
omission B-Life-Impact

Profound O
effects O
on O
cellular B-Physiological-Clinical
distribution O
and O
viral B-Physiological-Clinical

Similarly O
, O
no O
significant O
differences O
in O
urinary B-Physiological-Clinical
calcium I-Physiological-Clinical

GH O
treatment O
was O
well B-Physiological-Clinical

Patients O
were O
evaluated O
weekly O
, O
and O
gastrointestinal B-Physiological-Clinical
toxicities I-Physiological-Clinical
were O
graded O
according O
to O
the O
Late O
Effect O
of O
Normal O
Tissue-Subjective O
Objective O
Management O
Analytic O
( O
LENT-SOMA O
) O
toxicity B-Adverse-effects

The O
effect O
of O
vaccination B-Resource-use
on O
pig B-Physiological-Clinical

After O
rare O
non-targets O
N1 B-Physiological-Clinical
amplitudes I-Physiological-Clinical
at I-Physiological-Clinical
Fz I-Physiological-Clinical
decreased O
but O
P3 B-Physiological-Clinical

These O
results O
suggest O
that O
none O
of O
the O
three O
beta-blockers O
tested O
nor O
disopyramide O
phosphate O
is O
likely O
to O
reduce O
the O
mortality B-Mortality
from I-Mortality
acute I-Mortality
myocardial I-Mortality
infarction I-Mortality
when O
given O
prophylactically O
, O
although O
disopyramide O
phosphate O
does O
reduce O
the O
incidence O
of O
'serious O
' O
ventriicular B-Physiological-Clinical

Additional O
changes O
in O
BMD B-Physiological-Clinical
and O
bone B-Physiological-Clinical

Ranitidine O
pretreatment O
had O
no O
effect O
on O
triazolam B-Physiological-Clinical
's O
terminal B-Physiological-Clinical
elimination O
rate O
constant O
or O
on O
the O
time B-Physiological-Clinical
to I-Physiological-Clinical
reach I-Physiological-Clinical
maximum I-Physiological-Clinical
serum B-Physiological-Clinical

Children O
with O
neurodevelopmental O
disabilities O
, O
who O
had O
treatment O
resistant B-Physiological-Clinical
chronic I-Physiological-Clinical
delayed I-Physiological-Clinical
sleep I-Physiological-Clinical
phase O
syndrome B-Physiological-Clinical
and O
impaired B-Physiological-Clinical

In O
the O
subgroup O
of O
Avastin-treated O
eyes O
, O
multivariate O
analysis O
identified O
hemoglobin O
A1c O
as O
the O
strongest O
predictor O
of O
proliferative B-Physiological-Clinical
diabetic I-Physiological-Clinical

Using O
the O
multiplex O
assay O
, O
small O
borderline O
significant O
increases O
in O
matrix B-Physiological-Clinical
metalloproteinase-9 I-Physiological-Clinical
, O
interleukins B-Physiological-Clinical
( O
IL B-Physiological-Clinical
) O
-1 O
beta B-Physiological-Clinical
, O
6 O
and O
10 O
occurred O
7 O
hrs O
post O
exposure O
initiation O
, O
whereas O
E-selectin O
, O
intercellular O
adhesion O
molecule-1 O
, O
and O
vascular B-Physiological-Clinical
cell I-Physiological-Clinical
adhesion B-Physiological-Clinical
molecule B-Physiological-Clinical

There O
are O
no O
differences O
in O
terms O
of O
overall B-Mortality
survival I-Mortality
and O
distant B-Physiological-Clinical
disease-free I-Physiological-Clinical

For O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
the O
values O
for O
plasma B-Physiological-Clinical
APV I-Physiological-Clinical
AUC O
( O
0-tau O
) O
, O
C B-Physiological-Clinical
( O
max O
) O
, O
and O
C B-Physiological-Clinical
( I-Physiological-Clinical
tau I-Physiological-Clinical
) O
were O
26 O
, O
48 O
, O
and O
32 O
% O
higher O
, O
respectively O
, O
and O
the O
values O
for O
plasma B-Physiological-Clinical
RTV I-Physiological-Clinical

There O
effects O
on O
disability B-Life-Impact

Compliance O
rates O
were O
similar O
between O
groups O
, O
with O
mean O
( O
SD O
) O
compliance B-Life-Impact

A O
significant O
difference O
was O
found O
in O
the O
paracetamol O
pharmacokinetic B-Physiological-Clinical
parameter O
oral B-Physiological-Clinical
clearance I-Physiological-Clinical

The O
cumulative O
gastrointestinal B-Physiological-Clinical
( O
GI B-Physiological-Clinical
) O
/liver O
adverse B-Adverse-effects
events I-Adverse-effects
( O
AEs B-Adverse-effects
) O
discontinuation B-Life-Impact

Topical O
selamectin O
was O
found O
to O
be O
40.7-63.3 O
% O
effective O
( O
based O
on O
egg B-Physiological-Clinical
per O
gram O
method O
) O
in O
eliminating B-Physiological-Clinical
S O
. O
muris B-Physiological-Clinical

Periodically O
recorded O
were O
body B-Physiological-Clinical
weight O
, O
BP B-Physiological-Clinical
( O
mercury O
sphygmomanometer O
) O
, O
serum B-Physiological-Clinical
creatinine I-Physiological-Clinical
, O
electrolytes B-Physiological-Clinical
, O
complete B-Physiological-Clinical
blood I-Physiological-Clinical
cell I-Physiological-Clinical
counts I-Physiological-Clinical
, O
urine B-Physiological-Clinical
volume I-Physiological-Clinical
, O
drainage B-Physiological-Clinical

Measurements O
of O
American O
Urological B-Physiological-Clinical
Association O
symptom B-Physiological-Clinical
score O
, O
peak O
urine B-Physiological-Clinical
flow I-Physiological-Clinical
rate I-Physiological-Clinical
and O
prostate B-Physiological-Clinical
specific I-Physiological-Clinical

Clonidine O
increased O
tourniquet B-Life-Impact
tolerance I-Life-Impact
from O
33 O
to O
45 O
min O
( O
P O
= O
0.06 O
) O
and O
increased O
time B-Life-Impact
to I-Life-Impact
ambulation I-Life-Impact
, O
spontaneous B-Physiological-Clinical
voiding I-Physiological-Clinical

However O
, O
a O
timolol-induced O
reduction O
in O
respiratory B-Physiological-Clinical
function I-Physiological-Clinical
was O
observed O
only O
in O
the O
evening O
: O
percent O
forced B-Physiological-Clinical
expiratory I-Physiological-Clinical
volume I-Physiological-Clinical
in I-Physiological-Clinical
1 I-Physiological-Clinical
second I-Physiological-Clinical
, O
peak O
expiratory B-Physiological-Clinical
flow I-Physiological-Clinical
rate I-Physiological-Clinical
, O
and O
expiratory B-Physiological-Clinical
flow I-Physiological-Clinical

